Raymond James raised the firm's price target on Hinge Health to $80 from $70 and keeps an Outperform rating on the shares following last week's investor day. The firm now has "even more confidence" in Hinge's opportunity to expand eligible lives and members. In addition, the company's investments to diversify its care should continue to put upward pressure on yields, the analyst tells investors in a research note. Raymond James thinks the company's long-term growth opportunity is "multiples above" the current 4% level.
